Compounds > oleanolic acid 3-acetate
Page last updated: 2024-12-08

oleanolic acid 3-acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

oleanolic acid 3-acetate: from Gardenia jasminoides; RN given for (3beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID151202
CHEMBL ID486822
SCHEMBL ID828971
MeSH IDM0149405

Synonyms (25)

Synonym
olean-12-en-28-oic acid, 3-(acetyloxy)-, (3beta)-
oleanolic acid 3-acetate
(4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-acetoxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
3-o-acetyloleanolic acid
(4as,6ar,6as,6br,8ar,10s,12ar,14bs)-10-acetyloxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
CHEMBL486822
acetyl oleanolic acid
bdbm50102741
4339-72-4
AKOS016036262
SCHEMBL828971
AC-34649
3beta-acetoxyolean-12-en-28-acid
BS-16825
mfcd09752429
(4as,6as,6br,8ar,10s,12ar,12br,14bs)-10-acetoxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a(2h)-carboxylic acid
3-?o-?acetyloleanolic acid
CS-0023022
HY-N2618
C75167
3-(acetyloxy)olean-12-en-28-oic acid
DTXSID20963002
3--cetyloleanolic acid
A872702
3-o-acetyloleanolic acid; 3beta-3-acetoxyolean-12-en-28-oic acid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)21.50000.00053.49849.7600AID1166644
Protease Human immunodeficiency virus 1IC50 (µMol)102.00000.00000.81769.8500AID1075595; AID436490
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (27)

Processvia Protein(s)Taxonomy
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (68)

Assay IDTitleYearJournalArticle
AID376069Antibacterial activity against Porphyromonas gingivalis after 48 hrs by microtiter plate method1999Journal of natural products, Oct, Volume: 62, Issue:10
Activity of triterpenoid glycosides from the root bark of Mussaenda macrophylla against two oral pathogens.
AID1187413Inhibition of LPS-induced IL1-beta release in mouse RAW264.7 cells compound preincubated at 20 ug/ml for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Oleanolic acid analogs as NO, TNF-α and IL-1β inhibitors: synthesis, biological evaluation and docking studies.
AID338356Cytotoxicity against human Raji cells assessed as cell viability at 1000 mol ratio after 48 hrs relative to TPA
AID1617461Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1310455Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Semi-synthesis and antiproliferative evaluation of PEGylated pentacyclic triterpenes.
AID1187407Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Oleanolic acid analogs as NO, TNF-α and IL-1β inhibitors: synthesis, biological evaluation and docking studies.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1187408Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Oleanolic acid analogs as NO, TNF-α and IL-1β inhibitors: synthesis, biological evaluation and docking studies.
AID338353Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as early antigen activation at 10 mol ratio after 48 hrs relative to TPA
AID1166643Inhibition of purified human GST-tagged PTP-1B assessed as reversibility of enzyme activity using p-nitrophenylphosphate as substrate at 10 times IC50 after 1 hr incubation followed by 250 fold dilution by spectrophotometry2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of oleanolic acid derivatives: In vitro, in vivo and in silico studies for PTP-1B inhibition.
AID1075591Induction of apoptosis in mouse B16F10 cells assessed as early apoptotic cells at IC50 after 72 hrs by annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 3.9 +/- 0.4%)2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID1187412Inhibition of LPS-induced TNF-alpha release in mouse J774A1 cells compound preincubated at 20 ug/ml for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Oleanolic acid analogs as NO, TNF-α and IL-1β inhibitors: synthesis, biological evaluation and docking studies.
AID1075590Induction of apoptosis in mouse B16F10 cells assessed as early apoptotic cells at 2 X IC50 after 72 hrs by annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 3.9 +/- 0.4%)2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID1371010Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced superoxide anion generation by measuring superoxide dismutase SOD-inhibitable ferricytochrome c reduction incubated for 5 mins before fMLP/CB stimulation for 3 mins 2017Journal of natural products, 04-28, Volume: 80, Issue:4
Chemical Constituents and Anti-inflammatory Principles from the Fruits of Forsythia suspensa.
AID338352Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as early antigen activation at 100 mol ratio after 48 hrs relative to TPA
AID1156800Anticancer activity against human HepG2 cells assessed as cell viability after 48 hrs by MTT assay2014European journal of medicinal chemistry, Aug-18, Volume: 83Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID338355Cytotoxicity against human Raji cells assessed as cell viability at 5000 mol ratio after 48 hrs relative to TPA
AID1310456Potency index, ratio of oleanolic acid IC50 to compound IC50 for mouse B16F10 cells2016European journal of medicinal chemistry, Aug-08, Volume: 118Semi-synthesis and antiproliferative evaluation of PEGylated pentacyclic triterpenes.
AID1075586Induction of apoptosis in mouse B16F10 cells assessed as total apoptotic cells at 2 X IC50 after 72 hrs by annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 13.7 +/- 2.7%)2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID338358Cytotoxicity against human Raji cells assessed as cell viability at 10 mol ratio after 48 hrs relative to TPA
AID398030Spasmolytic activity in rabbit jejunum assessed as inhibition of K+-induced muscle contraction at 1 mg/mL after 30 mins2002Journal of natural products, Dec, Volume: 65, Issue:12
Structure and spasmolytic activity of eucalyptanoic acid from Eucalyptus camaldulensis var. obtusa and synthesis of its active derivative from oleanolic acid.
AID398029Spasmolytic activity in rabbit jejunum assessed as inhibition of calcium influx-mediated spontaneous muscle contraction at 1 mg/mL after 30 mins2002Journal of natural products, Dec, Volume: 65, Issue:12
Structure and spasmolytic activity of eucalyptanoic acid from Eucalyptus camaldulensis var. obtusa and synthesis of its active derivative from oleanolic acid.
AID266475Inhibition of rabbit muscle GPa2006Bioorganic & medicinal chemistry letters, Jun-01, Volume: 16, Issue:11
Pentacyclic triterpenes. Part 3: Synthesis and biological evaluation of oleanolic acid derivatives as novel inhibitors of glycogen phosphorylase.
AID379564Antihyperglycemic activity in Streptozotocin-induced diabetic Wistar rat assessed as decrease in blood glucose level at 31 mg/kg, po after 7 hrs2006Journal of natural products, Dec, Volume: 69, Issue:12
Antihyperglycemic activity and chemical constituents of Eysenhardtia platycarpa.
AID1075588Induction of apoptosis in mouse B16F10 cells assessed as late apoptotic cells at 2 X IC50 after 72 hrs by annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 9.8 +/- 2.2%)2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID1075584Induction of apoptosis in mouse B16F10 cells assessed as necrotic cells at 2 X IC50 after 72 hrs by annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 4.0 +/- 0.6%)2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID436490Inhibition of HIV1 protease2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Synthesis and evaluation of A-seco type triterpenoids for anti-HIV-1protease activity.
AID1075583Induction of ROS generation in mouse B16F10 cells at IC50 to 2 X IC50 after 72 hrs by rhodamine123/propidium iodide staining-based FACS analysis2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID1310454Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Semi-synthesis and antiproliferative evaluation of PEGylated pentacyclic triterpenes.
AID1166645Inhibition of TC-PTP (unknown origin) using p-nitrophenylphosphate as substrate by spectrophotometry2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of oleanolic acid derivatives: In vitro, in vivo and in silico studies for PTP-1B inhibition.
AID1617460Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1500873Inhibition of recombinant human CETP at 10 uM using fluorescent cholesteryl containing HDL after 3 hrs by fluorescence assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of pentacyclic triterpene 3β-ester derivatives as a new class of cholesterol ester transfer protein inhibitors.
AID201654Compound was tested for its cytotoxicity against human malignant melanoma cell line SK-MEL; NA = Not active1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis and evaluation of potential complement inhibitory semisynthetic analogs of oleanolic acid.
AID1075592Induction of apoptosis in mouse B16F10 cells assessed as normal cells at IC50 after 72 hrs by annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 77.9 +/- 1.5%)2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID1166642Inhibition of purified human GST-tagged PTP-1B using p-nitrophenylphosphate as substrate at 50 uM by spectrophotometry2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of oleanolic acid derivatives: In vitro, in vivo and in silico studies for PTP-1B inhibition.
AID232989The compound was tested for its apoptotic activity; no DNA migration observed1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis and evaluation of potential complement inhibitory semisynthetic analogs of oleanolic acid.
AID1371011Anti-inflammatory activity in human neutrophils assessed as inhibition of fMLP/CB-induced elastase release pre-incubated for 5 mins before fMLP/CB stimulation using MeO-Suc-Ala-Ala-Pro-Val-pnitroanilide as substrate2017Journal of natural products, 04-28, Volume: 80, Issue:4
Chemical Constituents and Anti-inflammatory Principles from the Fruits of Forsythia suspensa.
AID1166644Inhibition of purified human GST-tagged PTP-1B using p-nitrophenylphosphate as substrate by spectrophotometry2014European journal of medicinal chemistry, Nov-24, Volume: 87Synthesis of oleanolic acid derivatives: In vitro, in vivo and in silico studies for PTP-1B inhibition.
AID338350Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as early antigen activation at 5000 mol ratio after 48 hrs relative to TPA
AID338357Cytotoxicity against human Raji cells assessed as cell viability at 100 mol ratio after 48 hrs relative to TPA
AID1075594Induction of apoptosis in mouse B16F10 cells assessed as normal cells at 2 X IC50 after 72 hrs by annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 77.9 +/- 1.5%)2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID1617464Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID338351Inhibition of TPA-induced EBV-early antigen activation in human Raji cells assessed as early antigen activation at 1000 mol ratio after 48 hrs relative to TPA
AID1310453Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay2016European journal of medicinal chemistry, Aug-08, Volume: 118Semi-synthesis and antiproliferative evaluation of PEGylated pentacyclic triterpenes.
AID224273Percent inhibition of nitric oxide production induced by IFN-uM concentration2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Novel synthetic oleanane and ursane triterpenoids with various enone functionalities in ring A as inhibitors of nitric oxide production in mouse macrophages.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1310460Potency index, ratio of oleanolic acid IC50 to compound IC50 for human HepG2 cells2016European journal of medicinal chemistry, Aug-08, Volume: 118Semi-synthesis and antiproliferative evaluation of PEGylated pentacyclic triterpenes.
AID1617463Antiproliferative activity against human KB-VIN10 cells incubated for 72 hrs by SRB assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1156795Retention time of the compound by chromatography2014European journal of medicinal chemistry, Aug-18, Volume: 83Prediction of anti-tumor chemical probes of a traditional Chinese medicine formula by HPLC fingerprinting combined with molecular docking.
AID1674253Neuroprotective activity against amyloid beta (1 to 42 residues)-induced cell death in mouse HT22 cells assessed as increase in cell viability at 1 uM after 24 hrs by MTT assay (Rvb = 51.2%)2020Journal of natural products, 07-24, Volume: 83, Issue:7
Neuroprotective Effects of Triterpenoids from
AID1075587Induction of apoptosis in mouse B16F10 cells assessed as total apoptotic cells at IC50 after 72 hrs by annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 13.7 +/- 2.7%)2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID1187409Cytotoxicity mouse RAW264.7 cells assessed as cell viability by MTT assay relative to control2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Oleanolic acid analogs as NO, TNF-α and IL-1β inhibitors: synthesis, biological evaluation and docking studies.
AID1075593Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID1500868Inhibition of recombinant human CETP after 3 hrs using fluorescent cholesteryl containing HDL after 3 hrs by fluorescence assay2017European journal of medicinal chemistry, Oct-20, Volume: 139Discovery of pentacyclic triterpene 3β-ester derivatives as a new class of cholesterol ester transfer protein inhibitors.
AID1187411Inhibition of LPS-induced TNF-alpha release in mouse RAW264.7 cells compound preincubated at 20 ug/ml for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Oleanolic acid analogs as NO, TNF-α and IL-1β inhibitors: synthesis, biological evaluation and docking studies.
AID1075585Induction of apoptosis in mouse B16F10 cells assessed as necrotic cells at IC50 after 72 hrs by annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 4.0 +/- 0.6%)2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID1187414Inhibition of LPS-induced IL1-beta release in mouse J774A1 cells compound preincubated at 20 ug/ml for 1 hr before LPS treatment measured after 6 to 12 hrs by sandwich immunoassay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Oleanolic acid analogs as NO, TNF-α and IL-1β inhibitors: synthesis, biological evaluation and docking studies.
AID1617462Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay2019Journal of natural products, 11-22, Volume: 82, Issue:11
Discovery of an Oleanolic Acid/Hederagenin-Nitric Oxide Donor Hybrid as an EGFR Tyrosine Kinase Inhibitor for Non-Small-Cell Lung Cancer.
AID1187410Cytotoxicity against mouse J774A1 cells assessed as cell viability by MTT assay relative to control2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Oleanolic acid analogs as NO, TNF-α and IL-1β inhibitors: synthesis, biological evaluation and docking studies.
AID338354Inhibition of EBV-early antigen activation in human Raji cells assessed as early antigen activation at 1 uM ratio after 48 hrs
AID750462Antiviral activity against pseudo HCV infected in human 293T cells assessed as inhibition of HCV pseudo particles entry at 10 uM after 72 hrs by luciferase reporter gene assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Development of oleanane-type triterpenes as a new class of HCV entry inhibitors.
AID1604321Antiparasitic activity against Toxoplasma gondii2019European journal of medicinal chemistry, Dec-01, Volume: 183Recent progress on anti-Toxoplasma drugs discovery: Design, synthesis and screening.
AID376070Antibacterial activity against Streptococcus mutans after 48 hrs by microtiter plate method1999Journal of natural products, Oct, Volume: 62, Issue:10
Activity of triterpenoid glycosides from the root bark of Mussaenda macrophylla against two oral pathogens.
AID1075589Induction of apoptosis in mouse B16F10 cells assessed as late apoptotic cells at IC50 after 72 hrs by annexin V-FITC/propidium iodide staining-based FACS analysis (Rvb = 9.8 +/- 2.2%)2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID90586The compound was tested in vitro for its inhibition of the classical pathway activation of human complement; Not active1999Bioorganic & medicinal chemistry letters, Jul-19, Volume: 9, Issue:14
Synthesis and evaluation of potential complement inhibitory semisynthetic analogs of oleanolic acid.
AID1075595Inhibition of HIV1 recombinant protease expressed in Escherichia coli using Abz-Ala-Arg-Val-Nle-Tyr(NO2)-Glu-Ala-Nle-NH2 as substrate by FRET assay2014European journal of medicinal chemistry, Mar-03, Volume: 74Semi-synthesis of acylated triterpenes from olive-oil industry wastes for the development of anticancer and anti-HIV agents.
AID1310458Potency index, ratio of oleanolic acid IC50 to compound IC50 for human HT-29 cells2016European journal of medicinal chemistry, Aug-08, Volume: 118Semi-synthesis and antiproliferative evaluation of PEGylated pentacyclic triterpenes.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (2.86)18.7374
1990's3 (8.57)18.2507
2000's7 (20.00)29.6817
2010's21 (60.00)24.3611
2020's3 (8.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.74 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index5.35 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
caffeine
[no description available]		2.0310purine alkaloid;
trimethylxanthine		adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic
hydroxyzine
Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.		3.3110hydroxyether;
monochlorobenzenes;
N-alkylpiperazine		anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist
ketoprofen
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.		2.1310benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
niclosamide
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48). niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.		3.3110benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide		anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor
mannitol
[no description available]		2.3820mannitolallergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent
hydrazine
diamine : Any polyamine that contains two amino groups.		2.0210azane;
hydrazines		EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor
glycyrrhetinic acid
[no description available]		2.0810cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		immunomodulator;
plant metabolite
oleanolic acid
[no description available]		5.36170hydroxy monocarboxylic acid;
pentacyclic triterpenoid		plant metabolite
periplogenin
periplogenin: structure		2.0510
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.2110taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
ng-nitroarginine methyl ester
NG-Nitroarginine Methyl Ester: A non-selective inhibitor of nitric oxide synthase. It has been used experimentally to induce hypertension.		2.110alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor
ursolic acid
[no description available]		4.1540hydroxy monocarboxylic acid;
pentacyclic triterpenoid		geroprotector;
plant metabolite
betulinic acid
[no description available]		2.9740hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite
buparvaquone
buparvaquone: used in therapy of theileriasis; structure given in first source		3.3110
betulin
betulin: isolated from various white birch bark (BETULA). betulin : A pentacyclic triterpenoid that is lupane having a double bond at position 20(29) as well as 3beta-hydroxy and 28-hydroxymethyl substituents.		2.0710diol;
pentacyclic triterpenoid		analgesic;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
metabolite
hederagenin
[no description available]		2.830dihydroxy monocarboxylic acid;
pentacyclic triterpenoid;
sapogenin		plant metabolite
jacaranone
jacaranone: sedative; structure		2.0210
pinoresinol
(+)-pinoresinol : An enantiomer of pinoresinol having (+)-1S,3aR,4S,6aR-configuration.		2.1510pinoresinolhypoglycemic agent;
phytoestrogen;
plant metabolite
arjunolic acid
arjunolic acid: oleanane type; isol from Cochlospermum tinctorium (Bixaceae); structure given in first source; RN given refers to (2alpha,3beta,4alpha)-isomer; RN for cpd without isomeric designation not avail 12/89. arjunolic acid : A pentacyclic triterpenoid that is olean-12-en-28-oic acid substituted by hydroxy groups at positions 2, 3 and 23 (the 2alpha,3beta stereoisomer). Isolated from Symplocos lancifolia and Juglans sinensis, it exhibits antioxidant and antimicrobial activities.		2.0810hydroxy monocarboxylic acid;
pentacyclic triterpenoid		antibacterial agent;
antifungal agent;
antioxidant;
metabolite
maslinic acid
(2Alpha,3beta)-2,3-dihydroxyolean-12-en-28-oic acid: from Luehea divaricata and Agrimonia eupatoria		2.7930dihydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite
gypsogenin
gypsogenin: originally from Gypsophila species; structure in first source. gypsogenin : A sapogenin that is olean-12-en-28-oic acid substituted by a beta-hydroxy group at position 3 and an oxo group at position 23.		2.0810aldehyde;
monocarboxylic acid;
pentacyclic triterpenoid;
sapogenin
erythrodiol
[no description available]		2.110diol;
pentacyclic triterpenoid;
primary alcohol;
secondary alcohol		plant metabolite
quillaic acid
quillaic acid : A pentacyclic triterpenoid that is olean-12-ene substituted by hydroxy groups at positions 3 and 16, an oxo group at position 23 and a carboxy group at position 28 (the 3beta,16alpha stereoisomer).		2.0810aldehyde;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid		anti-inflammatory agent;
metabolite
procyanidin
Proanthocyanidins: Dimers and oligomers of flavan-3-ol units (CATECHIN analogs) linked mainly through C4 to C8 bonds to leucoanthocyanidins. They are structurally similar to ANTHOCYANINS but are the result of a different fork in biosynthetic pathways.		2.0510proanthocyanidin
daidzin
daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase. daidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).		2.1107-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative		plant metabolite
taraxasterol
taraxasterol: from Cirsium segetum. taraxasterol : A pentacyclic triterpenoid that is taraxastane with a beta-hydroxy group at position 3.		2.0510pentacyclic triterpenoid;
secondary alcohol		anti-inflammatory agent;
metabolite
matairesinol
matairesinol: lignan that is a central precursor in plants in the biosynthesis of numerous lignans (coordinate with specific); RN refers to (3R-trans)-isomer. (-)-matairesinol : A lignan that is gamma-butyrolactone in which the 3 and 4 positions are substituted by 4-hydroxy-3-methoxybenzyl groups (the 3R,4R-diastereomer).		2.1510gamma-lactone;
lignan;
polyphenol		angiogenesis inhibitor;
anti-asthmatic agent;
phytoestrogen;
plant metabolite
gefitinib
[no description available]		2.2110aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
proanthocyanidin a2
procyanidin A2: structure in first source. proanthocyanidin A2 : A proanthocyanidin obtained by the condensation of (-)-epicatechin units.		2.0510hydroxyflavan;
proanthocyanidin		angiogenesis modulating agent;
anti-HIV agent;
antioxidant;
metabolite
torcetrapib
[no description available]		2.1510(trifluoromethyl)benzenes;
carbamate ester;
quinolines		anticholesteremic drug;
CETP inhibitor
tanshinone ii a
tashinone IIA: a cardiovascular agent with antineoplastic activity; isolated from Salvia miltiorrhiza; structure in first source		3.3110abietane diterpenoid
sorafenib
[no description available]		2.1510(trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide		angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor
lupeol
[no description available]		2.0710pentacyclic triterpenoid;
secondary alcohol		anti-inflammatory drug;
plant metabolite
pomolic acid
pomolic acid: from Rosa woodsii & Hyptis capitata; structure in first source		2.0710triterpenoidmetabolite
ononin
[no description available]		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
monosaccharide derivative		plant metabolite
halofuginone
[no description available]		3.3110
gamma-sitosterol
clionasterol : A member of the class of phytosterols that is poriferast-5-ene carrying a beta-hydroxy substituent at position 3.		2.07103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
phytosterols		marine metabolite;
plant metabolite
ganoderic acid a
[no description available]		2.110triterpenoid
ganoderiol f
ganoderiol F: a ganoderma triterpene from Ganoderma amboinense; structure in first source		2.110triterpenoid
epipinoresinol
epipinoresinol : An enantiomer of pinoresinol having (+)-(1R,3aR,4S,6aR)-configuration.		2.1510pinoresinolmarine metabolite;
plant metabolite
caffeic acid
trans-caffeic acid : The trans-isomer of caffeic acid.		2.0510caffeic acidgeroprotector;
mouse metabolite
3-(3,4-dimethoxyphenyl)propenoic acid
3-(3,4-dimethoxyphenyl)propenoic acid: structure given in first source; RN given refers to parent cpd. 3,4-dimethoxycinnamic acid : A methoxycinnamic acid that is trans-cinnamic acid substituted by methoxy groups at positions 3' and 4' respectively.		1.9810methoxycinnamic acid
isoferulic acid
isoferulic acid: isomer of ferulic acid; structure. isoferulic acid : A ferulic acid consisting of trans-cinnamic acid bearing methoxy and hydroxy substituents at positions 4 and 3 respectively on the phenyl ring.		1.9810ferulic acidsantioxidant;
biomarker;
metabolite
tamoxifen
[no description available]		3.3110stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
1,1-diphenyl-2-picrylhydrazyl
1,1-diphenyl-2-picrylhydrazyl: A diphenyl picrate; the ability to decolorize this stable radical indicates reactivity of tested compounds (Banda, Anal Chem 46:1772-7 1974)		2.0210
phillygenin
phillygenin: cytoprotective lignan from Forsythia suspensa; structure in first source		2.1510
cytellin
cytellin: a phytosterol preparation of mainly B-sitosterol, that was marketed by Eli Lilly to lower cholesterol 1957 to 1982		2.0710
digitoxigenin
Digitoxigenin: 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide. A cardenolide which is the aglycon of digitoxin. Synonyms: Cerberigenin; Echujetin; Evonogenin; Thevetigenin.. digitoxigenin : A 5beta-cardenolide that is 5beta-cardanolide with hydroxy substituents at the 3beta- and 14beta-positions and double bond unsaturation at C(20)-C(22).		2.051014beta-hydroxy steroid;
3beta-hydroxy steroid
quercetin
[no description available]		2.25107-hydroxyflavonol;
pentahydroxyflavone		antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger
formononetin
[no description available]		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones		phytoestrogen;
plant metabolite
luteolin
[no description available]		2.1103'-hydroxyflavonoid;
tetrahydroxyflavone		angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist
7,3'-dihydroxy-4'-methoxyisoflavone
7,3'-dihydroxy-4'-methoxyisoflavone: isolated from Astragali radix; structure in first source. calycosin : A member of the class of 7-hydroxyisoflavones that is 7-hydroxyisoflavone which is substituted by an additional hydroxy group at the 3' position and a methoxy group at the 4' position.		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones		antioxidant;
metabolite
luteolin-7-glucoside
luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum. luteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.110beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone		antioxidant;
plant metabolite
apigetrin
apigetrin: structure given in first source. apigenin 7-O-beta-D-glucoside : A glycosyloxyflavone that is apigenin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.		2.110beta-D-glucoside;
dihydroxyflavone;
glycosyloxyflavone;
monosaccharide derivative		antibacterial agent;
metabolite;
non-steroidal anti-inflammatory drug
stigmasterol
stigmasta-5,22-dien-3-ol: isolated from freeze-dried powder of Blackberries (Rubus ursinus L.) which showed an activity on inhibition of chemocarcinogen. stigmasterol : A 3beta-sterol that consists of 3beta-hydroxystigmastane having double bonds at the 5,6- and 22,23-positions.		1.96103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
phytosterols;
stigmastane sterol		plant metabolite
kaempferol
[no description available]		2107-hydroxyflavonol;
flavonols;
tetrahydroxyflavone		antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite
myricetin
[no description available]		2107-hydroxyflavonol;
hexahydroxyflavone		antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite
forsythiaside
forsythiaside: RN given refers to (E)-isomer; structure given in first source; from the unripe fruit of Forsythia suspensa (qinglianquiao)		2.1510hydroxycinnamic acid
calycosin-7-o-beta-d-glucopyranoside
calycosin-7-O-beta-D-glucoside: from Radix Astragali. calycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage.		2.1104'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative
licochalcone a
licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer		3.3110chalcones
kaempferol-7-methyl ether
rhamnocitrin : A monomethoxyflavone that is the 7-methyl ether derivative of kaempferol.		210flavonols;
monomethoxyflavone;
trihydroxyflavone		plant metabolite
spd-304
SPD-304: structure in first source		2.110
guttiferone e
guttiferone E: isolated from the fruits of Garcinia pyrifera collected in Malaysia; structure in first source		3.3110
3 beta-o-acetylursolic acid
[no description available]		3.3110triterpenoid
beta-escin
[no description available]		2.0710
dalcetrapib
dalcetrapib: inhibits cholesteryl ester transfer protein (CETP)		2.1510anilide
chlorhexidine
Chlorhexidine: A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.. chlorhexidine : A bisbiguanide compound with a structure consisting of two (p-chlorophenyl)guanide units linked by a hexamethylene bridge.		210biguanides;
monochlorobenzenes		antibacterial agent;
antiinfective agent
jasplakinolide
jasplakinolide: cyclodepsipeptide isolated from marine sponge Jaspis; active against Candida; RN refers to 2S-(2R*,4E,6S*,8R*)-isomer; structure in first source. jaspamide : A cyclodepsipeptide isolated from Jaspis splendens and has been shown to exhibit antineoplastic activity. It is an actin polymerization and stabilization inducer.		3.3110cyclodepsipeptide;
phenols		actin polymerisation inducer;
animal metabolite;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
neuroprotective agent
3-oxo-12-ursen-28-oic acid
3-oxo-12-ursen-28-oic acid: from Potentilla chinensis		2.0510triterpenoid
anacetrapib
[no description available]		2.1510
diosgenin glucoside
diosgenin glucoside: RN given refers to (3beta,25R)-isomer; structure given in first source. diosgenin 3-O-beta-D-glucoside : A sterol 3-beta-D-glucoside having diosgenin as the sterol component.		2.110hexacyclic triterpenoid;
monosaccharide derivative;
spiroketal;
sterol 3-beta-D-glucoside		metabolite
phytosterols
Phytosterols: A class of organic compounds known as sterols or STEROIDS derived from plants.. phytosterols : Sterols similar to cholesterol which occur in plants and vary only in carbon side chains and/or presence or absence of a double bond.		1.9610
oleanonic acid
oleanonic acid: structure in first source		3.1350
astragaloside IV
[no description available]		2.110pentacyclic triterpenoid;
triterpenoid saponin		anti-inflammatory agent;
antioxidant;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
neuroprotective agent;
plant metabolite;
pro-angiogenic agent
2-hydroxyursolic acid
2-hydroxyursolic acid: isolated from the stem bark of Physocarpus intermedius; structure in first source		2.0710
ganoderic acid f
ganoderic acid F: isolated from Ganoderma lucidum; structure in first source		2.110triterpenoid
3mb-pp1
[no description available]		3.3110
nitd 609
NITD 609: an antimalarial and coccidiostat; structure in first source		3.3110
evacetrapib
[no description available]		2.1510benzazepine
ganoderic acid c2
ganoderic acid C2: from the fruiting body of Ganoderma; structure in first source		2.110triterpenoid
osimertinib
osimertinib: an EGFR tyrosine kinase inhibitor. osimertinib : A member of the class of aminopyrimidines that is 4-(1-methylindol-3-yl)pyrimidin-2-amine in which one of the amino hydrogens is replaced by a 2-methoxy-4-[2-(dimethylamino)ethyl](methyl)amino-5-acrylamidophenyl group. Used (as the mesylate salt) for treatment of EGFR T790M mutation positive non-small cell lung cancer.		2.2110acrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound		antineoplastic agent;
epidermal growth factor receptor antagonist
zaprinast
zaprinast: anaphylaxis inhibitor; structure		3.3110triazolopyrimidines
ConditionIndicatedRelationship StrengthStudiesTrials
Malignant Melanoma
[description not available]		0210
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		0210
Muscle Contraction
A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments.		02.0110
Hyperglycemia, Postprandial
Abnormally high BLOOD GLUCOSE level after a meal.		02.0310
Hyperglycemia
Abnormally high BLOOD GLUCOSE level.		02.0310
HIV Coinfection
[description not available]		02.0510
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		02.0510
Benign Neoplasms
[description not available]		03.0310
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.0310
Infection, Toxoplasma gondii
[description not available]		03.1210
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		03.1210
Toxoplasmosis
The acquired form of infection by Toxoplasma gondii in animals and man.		03.1210
Carcinoma, Non-Small Cell Lung
[description not available]		02.2110
Cancer of Lung
[description not available]		02.2110
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.2110
Lung Neoplasms
Tumors or cancer of the LUNG.		02.2110
Experimental Neoplasms
[description not available]		02.2510
Angiogenesis, Pathologic
[description not available]		02.2510
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.1710
Fatty Liver, Nonalcoholic
[description not available]		02.1710
Hyperlipemia
[description not available]		02.1710
Hyperlipidemias
Conditions with excess LIPIDS in the blood.		02.1710
Non-alcoholic Fatty Liver Disease
Fatty liver finding without excessive ALCOHOL CONSUMPTION.		02.1710
Carcinoma, Epidermoid
[description not available]		02.1710
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.5520
Lymph Node Metastasis
[description not available]		02.1710
Cancer of Mouth
[description not available]		02.1710
Carcinoma, Squamous Cell
A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)		02.1710
Mouth Neoplasms
Tumors or cancer of the MOUTH.		02.1710
Adjuvant Arthritis
[description not available]		02.1310
Rheumatoid Arthritis
[description not available]		02.1310
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		02.1310